tiprankstipranks
Trending News
More News >
Oxford Biomedica (otc) (DE:OXOA)
:OXOA
Germany Market

Oxford BioMedica (OXOA) Stock Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

OXOA Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Oxford
BioMedica
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OXOA Stock 12 Month Forecast

Average Price Target

€7.73
▲( 120.85% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Oxford BioMedica in the last 3 months. The average price target is €7.73 with a high forecast of €9.51 and a low forecast of €5.94. The average price target represents a 120.85% change from the last price of €3.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","5":"€5","10":"€10","2.5":"€2.5","7.5":"€7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9.5094656814,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€9.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.7297612103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.9412024881,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.94</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"May<br/>2024","9":"Oct<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.8145742831846152,4.289148566369231,4.763722849553846,5.238297132738461,5.712871415923077,6.187445699107693,6.662019982292308,7.136594265476923,7.611168548661539,8.085742831846154,8.56031711503077,9.034891398215386,{"y":9.5094656814,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.6776739392538462,4.015347878507693,4.3530218177615385,4.690695757015384,5.02836969626923,5.366043635523077,5.703717574776923,6.041391514030769,6.379065453284616,6.716739392538462,7.054413331792308,7.3920872710461545,{"y":7.7297612103,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.5400924990846154,3.7401849981692306,3.940277497253846,4.140369996338461,4.340462495423077,4.540554994507692,4.7406474935923075,4.940739992676923,5.140832491761539,5.340924990846154,5.54101748993077,5.741109989015385,{"y":5.9412024881,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.08,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€9.51Average Price Target€7.73Lowest Price Target€5.94
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:OXOA
Charles WestonRBC Capital
RBC Capital
€9.49
Buy
171.25%
Upside
Reiterated
04/14/25
Stifel Nicolaus Analyst forecast on DE:OXOA
James OrsborneStifel Nicolaus
Stifel Nicolaus
€5.93
Buy
69.53%
Upside
Reiterated
04/09/25
J.P. Morgan Analyst forecast on DE:OXOA
James GordonJ.P. Morgan
J.P. Morgan
€5.34€5.81
Hold
66.14%
Upside
Reiterated
12/03/24
Deutsche Bank  Analyst forecast on DE:OXOA
Paul CuddonDeutsche Bank
Deutsche Bank
€2.97€4.51
Hold
28.84%
Upside
Reiterated
09/24/24
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:OXOA
Charles WestonRBC Capital
RBC Capital
€9.49
Buy
171.25%
Upside
Reiterated
04/14/25
Stifel Nicolaus Analyst forecast on DE:OXOA
James OrsborneStifel Nicolaus
Stifel Nicolaus
€5.93
Buy
69.53%
Upside
Reiterated
04/09/25
J.P. Morgan Analyst forecast on DE:OXOA
James GordonJ.P. Morgan
J.P. Morgan
€5.34€5.81
Hold
66.14%
Upside
Reiterated
12/03/24
Deutsche Bank  Analyst forecast on DE:OXOA
Paul CuddonDeutsche Bank
Deutsche Bank
€2.97€4.51
Hold
28.84%
Upside
Reiterated
09/24/24
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oxford BioMedica

1 Month
xxx
Success Rate
9/21 ratings generated profit
43%
Average Return
+1.02%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +1.02% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
57%
Average Return
+1.12%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +1.12% per trade.
1 Year
Charles WestonRBC Capital
Success Rate
7/21 ratings generated profit
33%
Average Return
-4.10%
reiterated a buy rating last month
Copying Charles Weston's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.10% per trade.
2 Years
xxx
Success Rate
4/21 ratings generated profit
19%
Average Return
-30.08%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 19.05% of your transactions generating a profit, with an average return of -30.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OXOA Analyst Recommendation Trends

Rating
Sep 24
Oct 24
Nov 24
Dec 24
Apr 25
Strong Buy
5
3
3
1
3
Buy
0
0
1
1
1
Hold
3
2
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
5
6
4
5
In the current month, OXOA has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. OXOA average Analyst price target in the past 3 months is 7.73.
Each month's total comprises the sum of three months' worth of ratings.

OXOA Financial Forecast

OXOA Earnings Forecast

Next quarter’s earnings estimate for OXOA is -€0.09 with a range of -€0.09 to -€0.09. The previous quarter’s EPS was -€0.36. OXOA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.00% of the time in the same period. In the last calendar year OXOA has Preformed in-line its overall industry.
Next quarter’s earnings estimate for OXOA is -€0.09 with a range of -€0.09 to -€0.09. The previous quarter’s EPS was -€0.36. OXOA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.00% of the time in the same period. In the last calendar year OXOA has Preformed in-line its overall industry.

OXOA Sales Forecast

Next quarter’s sales forecast for OXOA is €90.73M with a range of €90.73M to €90.73M. The previous quarter’s sales results were €59.71M. OXOA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 41.67% of the time in the same period. In the last calendar year OXOA has Outperformed its overall industry.
Next quarter’s sales forecast for OXOA is €90.73M with a range of €90.73M to €90.73M. The previous quarter’s sales results were €59.71M. OXOA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 41.67% of the time in the same period. In the last calendar year OXOA has Outperformed its overall industry.

OXOA Stock Forecast FAQ

What is DE:OXOA’s average 12-month price target, according to analysts?
Based on analyst ratings, Oxford Biomedica (otc)’s 12-month average price target is 7.73.
    What is DE:OXOA’s upside potential, based on the analysts’ average price target?
    Oxford Biomedica (otc) has 120.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Oxford Biomedica (otc) a Buy, Sell or Hold?
          Oxford Biomedica (otc) has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Oxford Biomedica (otc)’s share price target?
            The average share price target for Oxford Biomedica (otc) is 7.73. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €9.51 ,and the lowest forecast is €5.94. The average share price target represents 120.85% Increase from the current price of €3.5.
              What do analysts say about Oxford Biomedica (otc)?
              Oxford Biomedica (otc)’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Oxford Biomedica (otc)?
                To buy shares of DE:OXOA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis